Clinical trials: Cardioprotection, active
Cardiotoxicity
Cardioprotection Effect of Linagliptin
1. Background and Rationale Breast cancer is one of the most common malignancies affecting women worldwide and represents a major health burden in Egypt.
- Trial name
- Linagliptin (NCT07852546)
- Testing
- Doxorubicin, Empaglifloz 5 mg orally once daily
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Tanta University
Breast Cancer, Heart Failure
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
- Trial name
- PROTECTAA (NCT06304857)
- Testing
- Dapagliflozin
- Where
- 3 sites in Poland
- Volunteers
- 188 people
- Sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland
Empgliflozin Cardioprotective Effect
Cardioprotective Effect of Empagliflozin in Breast Cancer Patients
Background: Doxorubicin (DOX) remains a cornerstone in adjuvant and neoadjuvant therapy for breast cancer, but its utility is hindered by dose-dependent cardiotoxicity.
- Trial name
- NCT07815808
- Testing
- Empagliflozin (EMPA), Metformin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI)
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
The goal of this clinical trial is to learn if giving the drug empagliflozin before versus after a heart procedure called primary PCI (percutaneous coronary intervention) affects how much heart muscle is damaged during a heart…
- Conditions
- ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI), Coronary Artery Disease
- Trial name
- TEMPO-STEMI (NCT07749014)
- Testing
- empagliflozin
- Where
- Pakistan
- Volunteers
- 480 people
- Sponsor
- Rehman Medical Institute - RMI
Breast Cancer, Doxorubicin Induced Cardiomyopathy
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing…
- Trial name
- NCT07370506
- Testing
- Telmisartan, Doxorubicin (DOX)
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Tanta University
Cardiotoxicity
Cardioprotection on Chemotherapy-Induced Cardiotoxicity
The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.
- Trial name
- NCT06853951
- Testing
- ACE Inhibitors, β -Blockers
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Dialysis, Cardioprotection
Exercise Intensity
Patients receiving regular hemodialysis (HD) treatments are at a higher risk of cardiovascular events and death as HD can cause a decrease in the pumping of the heart during treatment called 'stunning'.
- Trial name
- NCT07119593
- Testing
- Intradialytic Cycling
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Myocardial Infarction, Reperfusion Injury, Myocardial
Trans-coronary Cooling and Dilution for Cardioprotection During Revascularisation for ST-elevation Myocardial Infarction
A heart attack (myocardial infarction) occurs when an artery supplying blood to the heart is suddenly blocked resulting in damage to the heart muscle.
- Trial name
- STEMI-Cool (NCT06128993)
- Testing
- Transcoronary cooling and dilution, Standard of care
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive…
- Conditions
- Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly, Antineoplastic Agents, Cardiotoxicity
- Trial name
- CARTIER (NCT03711110)
- Testing
- Intensive cardiovascular monitoring, No intervention
- Where
- 14 sites in Spain
- Volunteers
- 514 people
- Sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Hip Fracture, Perioperative Myocardial Injury
Nerve Block and Perioperative Myocardial Injury in Elderly Hip Fracture
This single-center, retrospective cohort study evaluates whether a single preoperative peripheral nerve block can reduce the risk of perioperative myocardial injury in elderly patients undergoing delayed hip fracture surgery…
- Conditions
- Hip Fracture, Perioperative Myocardial Injury, Myocardial Injury After Noncardiac Surgery
- Trial name
- PNB-CARD (NCT07751146)
- Testing
- PNB, Non-PNB
- Volunteers
- 500 people
- Sponsor
- Tongji Hospital
Heart Failure
Finerenone Plus SGLT2 Inhibitors in Heart Failure
The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure.
- Trial name
- FIN-SGLT2-HF (NCT07351864)
- Testing
- Finerenone, dapagliflozine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Heart Failure
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors >50 years old.
- Trial name
- NCT04983823
- Testing
- Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP), Usual care
- Where
- Australia
- Volunteers
- 820 people, healthy volunteers welcome
- Sponsor
- Baker Heart and Diabetes Institute
Myocardial Infarction, Reperfusion Injury
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI).
- Conditions
- Myocardial Infarction, Reperfusion Injury, AMI, STEMI (ST Elevation MI)
- Trial name
- PROTECT-MI (NCT07362446)
- Testing
- Xolatryp
- Where
- 8 sites in Australia
- Volunteers
- 300 people
- Sponsor
- Nyrada Pty Ltd
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, chronic…
- Conditions
- Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome
- Trial name
- NCT03589729
- Testing
- Cladribine, Cytarabine, Dexrazoxane Hydrochloride
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Hemodialysis, Cardioprotection
Exercise Preconditioning to Protect Against Dialysis-induced Cardiac Injury
The goal of this study is to determine what happens to the heart muscle contraction when people cycle before their hemodialysis treatment.
- Trial name
- NCT06735378
- Testing
- Intradialytic Cycling
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
AML, Acute Myeloid Leukemia
Cardioprotection in AML
Patients with acute myeloid leukemia (AML) often receive a drug called daunorubicin. Daunorubicin is a type of drug called an anthracycline, which increases the risk of some damage to the heart.
- Trial name
- AML 001 (NCT04977180)
- Testing
- Cardioprotection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Virginia
Dialysis Patients
Intradialytic Exercise With Blood Flow Restriction in Hemodialysis Patients
The main objective is to evaluate in hemodialysis patients the effects of two intradialytic rehabilitation programs based on physical exercise, with or without the application of blood flow restriction, on myocardial stunning and…
- Trial name
- ERO-CARD (NCT07269379)
- Testing
- Chronic phase - HDEX/HDBFRE, Acute phase - HDEX/HDBFRE
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- University of Avignon
STEMI, Remote Ischaemic Conditioning
Remote Ischaemic Conditioning in STEMI Patients in AFRICA
The RIC-AFRICA trial is a multi-centre, sham-controlled, randomised controlled trial (RCT) involving 1400 ST-segment elevation myocardial infarction (STEMI) patients presenting within ≤ 24 hours of myocardial infarction (MI)…
- Conditions
- STEMI, Remote Ischaemic Conditioning, Myocardial Reperfusion Injury
- Trial name
- RIC-AFRICA (NCT04813159)
- Testing
- Remote Ischaemic Conditioning (RIC)
- Where
- 20 sites in Kenya, Mozambique and 4 more
- Volunteers
- 1,400 people
- Sponsor
- University of Cape Town
Coronary Artery Disease
Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation
This is an open-label, randomized, multicenter Phase II clinical study designed to evaluate the cardioprotective effect, to determine the optimal dosages and duration of inhalation, and to assess the clinical safety of the…
- Trial name
- NCT07397351
- Testing
- Aroxxen
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- Research Institute of Geroprotective Technologies
Breast Cancer, Neoplasm, Breast
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020.
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents
- Trial name
- NCT05465031
- Testing
- Sacubitril-valsartan
- Where
- 4 sites in Poland
- Volunteers
- 600 people
- Sponsor
- Silesian Centre for Heart Diseases